News

July 16, 2024

Operator independent continuous ultrasound monitoring of diaphragm excursion predicts successful weaning from mechanical ventilation: a prospective observational study, Demoule et al. Critical Care (2024) 28:245.

July 21, 2023

RESPINOR announces new Chair of the Board

December 9, 2022

First patient included in the multicenter, multinational DE-RISK WF II study in Europe

January 4, 2022

RESPINOR is strengthening the team preparing for commercialization of DXT

October 15, 2021

RESPINOR AS Successfully completed Private Placement of approx. NOK 20 million (€ 2,0 million)

June 18, 2021

RESPINOR has started the last phase of the clinical program, DE-RISK-WF study in Europe, with DXT before regulatory submission (EU and USA)

April 22, 2021

Interview: The winners of the NLSInvest Rising Star Award

April 20, 2021

RESPINOR Announced Winner at the Nordic Life Science Investment Days

March 23, 2021

Kitron and RESPINOR in MedTech partnership

December 11, 2020

RESPINOR awarded 14.2M NOKs from the Research Council of Norway

May 4, 2020

RESPINOR winner of the European Innovation Councils (EIC) ePitching event for COVID-19 solutions

March 6, 2020

RESPINOR made Deloitte’s Technology Fast 50 list

June 21, 2019

RESPINOR featured in Kapital magazine – Norway’s biggest financial magazine

April 17, 2019

First patient enrolled in RESPINOR’s mechanical ventilation WEAN-US study at Hospitalier Pitié-Salpêtrière in Paris, France.

March 26, 2019

First patient enrolled in RESPINOR’s weaning study at St.Olav’s hospital in Trondheim, Norway.

March 8, 2019

RESPINOR at EIC investor’s day at Nasdaq Stockholm

December 12, 2018

DNB Nordic Healthcare Conference 2018, Oslo, Norway

December 4, 2018

RESPINOR DXT tested with principal investigator prior to study commencing in Paris, France

October 15, 2018

RESPINOR part of Norwegian Business Delegation to Beijing, China

September 5, 2018

Market introduction for Norwegian Health Tech Companies to Minneapolis, US

June 25, 2018

RESPINOR AS obtained ISO 13485:2016 certification

April 20, 2018

3.2 million patients are using respirator every year – Norwegian invention makes the costly treatment less expensive

January 31, 2018

Respinor AS has passed Stage 1 of the ISO certification process after no non-conformities were found. The next and final audit is scheduled for May 2018.

October 28, 2017

Test of novel device to measure respiratory function presented at international conference in Milan

February 7, 2017

Respinor ranked number one of a total of 237 in Europe

December 7, 2016

Recent updates from RESPINOR

Operator independent continuous ultrasound monitoring of diaphragm excursion predicts successful weaning from mechanical ventilation: a prospective observational study, Demoule et al. Critical Care (2024) 28:245.

RESPINOR announces new Chair of the Board

First patient included in the multicenter, multinational DE-RISK WF II study in Europe

RESPINOR is strengthening the team preparing for commercialization of DXT

RESPINOR AS Successfully completed Private Placement of approx. NOK 20 million (€ 2,0 million)

RESPINOR has started the last phase of the clinical program, DE-RISK-WF study in Europe, with DXT before regulatory submission (EU and USA)

Interview: The winners of the NLSInvest Rising Star Award

RESPINOR Announced Winner at the Nordic Life Science Investment Days

Kitron and RESPINOR in MedTech partnership

RESPINOR awarded 14.2M NOKs from the Research Council of Norway

RESPINOR winner of the European Innovation Councils (EIC) ePitching event for COVID-19 solutions

RESPINOR made Deloitte’s Technology Fast 50 list

RESPINOR featured in Kapital magazine – Norway’s biggest financial magazine

First patient enrolled in RESPINOR’s mechanical ventilation WEAN-US study at Hospitalier Pitié-Salpêtrière in Paris, France.

First patient enrolled in RESPINOR’s weaning study at St.Olav’s hospital in Trondheim, Norway.

RESPINOR at EIC investor’s day at Nasdaq Stockholm

DNB Nordic Healthcare Conference 2018, Oslo, Norway

RESPINOR DXT tested with principal investigator prior to study commencing in Paris, France

RESPINOR part of Norwegian Business Delegation to Beijing, China

Market introduction for Norwegian Health Tech Companies to Minneapolis, US

RESPINOR AS obtained ISO 13485:2016 certification

3.2 million patients are using respirator every year – Norwegian invention makes the costly treatment less expensive

Respinor AS has passed Stage 1 of the ISO certification process after no non-conformities were found. The next and final audit is scheduled for May 2018.

Test of novel device to measure respiratory function presented at international conference in Milan

Respinor ranked number one of a total of 237 in Europe

Award winner EVS

Links

Links

Contact

Recent updates from RESPINOR

Operator independent continuous ultrasound monitoring of diaphragm excursion predicts successful weaning from mechanical ventilation: a prospective observational study, Demoule et al. Critical Care (2024) 28:245.

RESPINOR announces new Chair of the Board

First patient included in the multicenter, multinational DE-RISK WF II study in Europe

RESPINOR is strengthening the team preparing for commercialization of DXT

RESPINOR AS Successfully completed Private Placement of approx. NOK 20 million (€ 2,0 million)

RESPINOR has started the last phase of the clinical program, DE-RISK-WF study in Europe, with DXT before regulatory submission (EU and USA)

Interview: The winners of the NLSInvest Rising Star Award

RESPINOR Announced Winner at the Nordic Life Science Investment Days

Kitron and RESPINOR in MedTech partnership

RESPINOR awarded 14.2M NOKs from the Research Council of Norway

RESPINOR winner of the European Innovation Councils (EIC) ePitching event for COVID-19 solutions

RESPINOR made Deloitte’s Technology Fast 50 list

RESPINOR featured in Kapital magazine – Norway’s biggest financial magazine

First patient enrolled in RESPINOR’s mechanical ventilation WEAN-US study at Hospitalier Pitié-Salpêtrière in Paris, France.

First patient enrolled in RESPINOR’s weaning study at St.Olav’s hospital in Trondheim, Norway.

RESPINOR at EIC investor’s day at Nasdaq Stockholm

DNB Nordic Healthcare Conference 2018, Oslo, Norway

RESPINOR DXT tested with principal investigator prior to study commencing in Paris, France

RESPINOR part of Norwegian Business Delegation to Beijing, China

Market introduction for Norwegian Health Tech Companies to Minneapolis, US

RESPINOR AS obtained ISO 13485:2016 certification

3.2 million patients are using respirator every year – Norwegian invention makes the costly treatment less expensive

Respinor AS has passed Stage 1 of the ISO certification process after no non-conformities were found. The next and final audit is scheduled for May 2018.

Test of novel device to measure respiratory function presented at international conference in Milan

Respinor ranked number one of a total of 237 in Europe

Award winner EVS

Subscribe now

Links

Links

Contact